Axogen’s $200 million BioCircuit deal bets on wider adoption of sutureless nerve repair

Axogen is betting $200 million on making nerve repair easier for more surgeons, agreeing to buy BioCircuit Technologies and pricing a stock sale to help pay for it. The acquisition would put BioCircuit’s NerveTape device behind Axogen’s sales force and hospital relationships, pairing a growing product business with a broader commercial network.

Axogen announced the agreement on September 10, following its signing on September 9. The merger is expected to close in the fourth quarter of 2026; the separate share offering is expected to close September 11, subject to customary conditions. Both remain pending in the September 10 announcements.

Sales momentum shapes the purchase price

BioCircuit generated $11 million in revenue in 2025, according to Axogen’s investor presentation. Its second-quarter 2026 sales represented an annualized revenue run rate of approximately $24 million. That extrapolates one quarter’s sales over a year; it is neither reported full-year revenue nor a forecast.

Axogen reported $225.2 million in 2025 revenue in the same presentation. BioCircuit’s $11 million was about 4.9% of that amount, while the $200 million base purchase price was nearly nine-tenths of Axogen’s annual revenue. The comparison illustrates the commitment’s size relative to the buyer’s business, rather than its available funding.

The base price amounts to about 18.2 times BioCircuit’s 2025 revenue, or about 8.3 times its annualized second-quarter run rate. These calculations use the unadjusted cash price, rather than a final transaction valuation. The difference underscores how much the price depends on the sales momentum investors use as their reference point.

BioCircuit was profitable on a standalone EBITDA basis, with approximately 80% gross margins, for the trailing 12 months ended May 31, 2026. EBITDA measures earnings before interest, taxes, depreciation and amortization; that profitability measure does not establish net income. As of June 2026, BioCircuit reported more than 14,000 NerveTape implants sold and more than 400 hospital and ambulatory surgery center accounts.

A simpler repair method meets a broader sales network

BioCircuit’s two core products serve different repair needs. NerveTape repairs breaks in peripheral nerves when bending the affected limb can bring the nerve ends together. ConformaWrap manages peripheral nerve injuries where there is no gap. Axogen says NerveTape lets surgeons align, connect and protect severed nerves without microsutures—the tiny stitches used to join nerve ends. Reducing reliance on microsurgical skills could make repair accessible to more surgeons and care settings.

“NerveTape’s sutureless approach makes high-quality nerve repair simpler and more accessible for surgeons,” Axogen President and Chief Executive Officer Michael Dale said in the acquisition announcement.

Axogen already markets Avance nerve graft products and Axoguard nerve connectors and protectors. It expects its direct sales force, surgeon relationships and hospital contracting infrastructure to accelerate NerveTape adoption. BioCircuit’s existing sales and accounts establish a commercial foothold; further expansion remains the acquisition’s promise.

The FDA’s record for Nerve Tape, application K210665, shows a July 15, 2022 substantial-equivalence decision under the 510(k) pathway. The device is FDA-cleared.

Offering costs narrow the cash available

Axogen priced 4,910,000 new common shares at $42.50 each. All are being sold by the company, raising capital while diluting existing holders’ percentage ownership.

The prospectus illustrates that dilution using 53,656,293 shares outstanding on June 30 and 58,566,293 after the base offering. New shares would represent about 8.4% of that adjusted total. This is a historical-base illustration, not September 10 ownership: it excludes later option exercises and restricted-stock-unit settlements, shares potentially issuable under outstanding awards and equity plans, and the underwriters’ additional-share option.

The offering price is also about 10.1% below the $47.27 last reported Nasdaq sale price on September 9, as quoted in the prospectus. That compares the financing price with the prior day’s trading price; it does not describe a market reaction to the deal.

The base offering’s gross proceeds are $208,675,000, or approximately $208.7 million. Underwriters pay Axogen $39.95 a share, retaining a $2.55-per-share discount. That totals $12,520,500 and leaves $196,154,500 before other offering expenses.

The final prospectus supplement estimates those additional expenses at approximately $700,000, bringing expected net proceeds to approximately $195.5 million. That is about $4.5 million below the acquisition’s $200 million base price, before acquisition fees and purchase-price adjustments. Offering expenses and acquisition costs are separate deductions.

Underwriters have a 30-day option to buy up to 736,500 additional shares. For full exercise, the prospectus estimates approximately $224.8 million in net proceeds. Applying the disclosed $39.95-per-share proceeds and the same $700,000 expense estimate mechanically gives $224.878 million, which rounds to $224.9 million. The small difference leaves the full-exercise figure as an issuer estimate rather than an exact reconciliation of those components. Neither scenario establishes that the option has been exercised.

The prospectus also supplies balance-sheet context: Axogen had $94.572 million in cash and cash equivalents and $16.840 million in investments as of June 30, 2026. Its capitalization table shows $290.027 million in cash after adjusting for the base offering. That hypothetical figure excludes the acquisition and the spending of proceeds on it; neither figure represents September 10 cash or a post-acquisition balance.

The prospectus’s Use of Proceeds and Capitalization sections do not assign a specific amount of existing cash to the purchase. Historical cash provides funding context, but does not establish how much Axogen will ultimately contribute from its balance sheet.

Axogen intends to use substantially all net offering proceeds for acquisition consideration and related fees and expenses, with any remainder for general corporate purposes, including working capital and capital expenditures. The purchase price itself adjusts for cash, debt, transaction expenses and net working capital. At closing, $1 million of estimated consideration would be withheld pending the post-closing adjustment. The agreement caps both an upward adjustment and a downward adjustment at $1 million. If the final calculation reduces consideration, Axogen can permanently retain the corresponding portion of the holdback and return the rest; otherwise it releases the holdback and pays any capped upward adjustment.

The merger carries a separate funding obligation

The offering can proceed even if the acquisition does not. If the BioCircuit deal falls through, Axogen intends to use the proceeds for general corporate purposes.

The merger has no financing condition. Axogen committed to obtain sufficient funding within 90 days of signing; failure would breach the agreement. Pricing the stock sale advances the financing plan but does not itself complete that obligation.

Both boards approved the transaction. Remaining merger conditions include consent under an inbound intellectual-property license, conversion of BioCircuit’s outstanding convertible notes into common stock and the spin-out of its unrelated electronics research and development business to its stockholders. Axogen says regulatory approvals are not expected to be required for the merger.

Either party may terminate if the deal has not been completed by December 31, 2026, subject to the agreement’s limitations. There is no merger termination fee, but that does not eliminate liability for a breach. The funding covenant gives BioCircuit all available legal remedies, including specific performance—a court order requiring contractual performance. The agreement also preserves liability or damages from a material breach after termination.

Closing will set the timetable for guidance

Axogen expects the acquisition to increase revenue growth, adjusted EBITDA margin and adjusted earnings per share in the first year after closing, while maintaining positive free cash flow. Integration could nevertheless consume resources, cause unanticipated costs or delay the benefits, its filing warns.

The immediate milestone is the expected September 11 offering closing, followed by satisfaction of the merger conditions. Axogen plans to update full-year 2026 guidance after acquisition completion. Assuming a 2026 closing, it expects BioCircuit to add to 2027 revenue and improve gross margin and adjusted EBITDA margin. Full-year 2027 guidance is planned for the first quarter of 2027.

Correction: An earlier version incorrectly said BioCircuit’s financial details were unavailable. Axogen’s presentation disclosed 2025 revenue, an annualized second-quarter 2026 revenue run rate, standalone EBITDA profitability and gross margins. The article also previously described NerveTape as FDA-approved; the FDA record establishes 510(k) clearance.